ORIC PHARMACEUTICALS INC (ORIC) competitors & alternatives
Health Care · NASDAQ
ORIC PHARMACEUTICALS INC (ORIC)'s top competitors and alternatives — its most similar public companies — include Exelixis (EXEL), KURA ONCOLOGY INC (KURA), PERSPECTIVE THERAPEUTICS INC (CATX), NURIX THERAPEUTICS INC (NRIX), Revolution Medicines (RVMD), TANGO THERAPEUTICS INC (TNGX), ADC THERAPEUTICS SA (ADCT), PRELUDE THERAPEUTICS INC (PRLD), FOGHORN THERAPEUTICS INC (FHTX), ASTRAZENECA PLC (AZN), CYTOMX THERAPEUTICS INC (CTMX) and ERASCA INC (ERAS). These are ORIC PHARMACEUTICALS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top ORIC competitors & alternatives
-
ExelixisEXELHealth Care
Exelixis is a profitable oncology company commercializing the multi-kinase inhibitor cabozantinib across multiple cancer indications while advancing a pipeline…
$54.98 (as of 2026-07-22) · market cap $14.0B
-
KURA ONCOLOGY INCKURAHealth Care
Clinical-stage oncology company commercializing KOMZIFTI for cancer and advancing a pipeline of targeted therapeutics through strategic partnerships.
$10.54 (as of 2026-07-22) · market cap $944M
-
PERSPECTIVE THERAPEUTICS INCCATXHealth Care
Perspective Therapeutics is a clinical-stage oncology company pioneering targeted alpha therapy (TAT) to treat cancer through a proprietary radiopharmaceutical…
$2.97 (as of 2026-07-22) · market cap $337M
-
NURIX THERAPEUTICS INCNRIXHealth Care
Clinical-stage biotech pioneering AI-powered targeted protein degradation medicines for cancer and autoimmune diseases, with Phase 2 lead candidate…
$23.60 (as of 2026-07-22) · market cap $2.4B
-
Revolution MedicinesRVMDHealth Care
A precision oncology biotech in clinical development stages, pursuing targeted cancer therapies with no approved products yet but backed by substantial capital.
$183.03 (as of 2026-07-22) · market cap $39.0B
-
TANGO THERAPEUTICS INCTNGXHealth Care
A precision oncology company utilizing a proprietary functional genomics platform to discover and develop targeted, synthetic-lethal cancer therapies.
$28.10 (as of 2026-07-22) · market cap $4.6B
-
ADC THERAPEUTICS SAADCTHealth Care
ADC Therapeutics develops antibody-drug conjugates (ADCs) targeting hematologic and solid tumors, with its lead product ZYNLONTA commercialized for lymphoma.
$1.24 (as of 2026-07-22) · market cap $158M
-
PRELUDE THERAPEUTICS INCPRLDHealth Care
An early-stage biopharma company developing novel small-molecule drug candidates targeting protein-driven disease mechanisms.
$3.92 (as of 2026-07-22) · market cap $313M
-
FOGHORN THERAPEUTICS INCFHTXHealth Care
Precision biotechnology company developing chromatin-targeting small molecule therapeutics to treat cancer and other serious diseases by correcting abnormal…
$5.21 (as of 2026-07-22) · market cap $306M
-
ASTRAZENECA PLCAZN
Leading global biopharmaceutical company developing targeted oncology, cardiovascular, and rare disease treatments backed by a strong R&D pipeline.
$169.73 (as of 2026-07-22) · market cap $193.7B
-
CYTOMX THERAPEUTICS INCCTMXHealth Care
CytomX is developing conditionally activated cancer therapies using its PROBODY platform to enable selective tumor targeting with reduced systemic toxicity,…
$3.33 (as of 2026-07-22) · market cap $724M
-
ERASCA INCERASHealth Care
A precision oncology company developing first-in-class RAS/MAPK pathway-targeting therapies for cancers driven by the most frequently mutated oncogene…
$19.51 (as of 2026-07-22) · market cap $6.8B
Not quite? Describe exactly what you want →
Peers are ORIC PHARMACEUTICALS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: ORIC PHARMACEUTICALS INC (ORIC).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.